Forest Celexa, Lexapro Off-Label Promotion, Kickbacks Alleged In DoJ Suit
Executive Summary
Forest waged an extensive campaign to get doctors to prescribe its antidepressants Lexapro and Celexa for off-label use in children, while concealing data that Celexa was no more effective than placebo in pediatric patients, and carried an increased risk of suicide attempts, the Department of Justice claims in a 1complaint filed against the company